The Impact of Same-Day Antiretroviral Therapy Initiation Under the World Health Organization Treat-All Policy.
Adolescent
Adult
Anti-HIV Agents
/ therapeutic use
Antitubercular Agents
/ therapeutic use
Eswatini
Female
HIV Infections
/ drug therapy
Humans
Male
Middle Aged
Patient Dropouts
Policy
Public Sector
Retrospective Studies
Survival Analysis
Time-to-Treatment
Tuberculosis
/ drug therapy
World Health Organization
Young Adult
Eswatini
HIV
TMLE
rapid ART
same-day ART
treat-all
Journal
American journal of epidemiology
ISSN: 1476-6256
Titre abrégé: Am J Epidemiol
Pays: United States
ID NLM: 7910653
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
received:
30
04
2020
revised:
27
01
2021
accepted:
09
02
2021
pubmed:
13
2
2021
medline:
26
8
2021
entrez:
12
2
2021
Statut:
ppublish
Résumé
Rapid initiation of antiretroviral therapy (ART) is recommended for people living with human immunodeficiency virus (HIV), with the option to start treatment on the day of diagnosis (same-day ART). However, the effect of same-day ART remains unknown in realistic public sector settings. We established a cohort of ≥16-year-old patients who initiated first-line ART under a treat-all policy in Nhlangano (Eswatini) during 2014-2016, either on the day of HIV care enrollment (same-day ART) or 1-14 days thereafter (early ART). Directed acyclic graphs, flexible parametric survival analysis, and targeted maximum likelihood estimation (TMLE) were used to estimate the effect of same-day-ART initiation on a composite unfavorable treatment outcome (loss to follow-up, death, viral failure, treatment switch). Of 1,328 patients, 839 (63.2%) initiated same-day ART. The adjusted hazard ratio of the unfavorable outcome was higher, 1.48 (95% confidence interval: 1.16, 1.89), for same-day ART compared with early ART. TMLE suggested that after 1 year, 28.9% of patients would experience the unfavorable outcome under same-day ART compared with 21.2% under early ART (difference: 7.7%; 1.3%-14.1%). This estimate was driven by loss to follow-up and varied over time, with a higher hazard during the first year after HIV care enrollment and a similar hazard thereafter. We found an increased risk with same-day ART. A limitation was that possible silent transfers that were not captured.
Identifiants
pubmed: 33576383
pii: 6133987
doi: 10.1093/aje/kwab032
pmc: PMC8327202
doi:
Substances chimiques
Anti-HIV Agents
0
Antitubercular Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1519-1532Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.
Références
Int Health. 2018 Mar 1;10(2):78-83
pubmed: 29342259
Glob Health Action. 2017;10(1):1330915
pubmed: 28640661
PLoS Med. 2019 Jun 10;16(6):e1002822
pubmed: 31181056
PLoS One. 2013 Oct 15;8(10):e77101
pubmed: 24143205
Science. 2012 Jul 20;337(6092):298-300
pubmed: 22798404
Trop Med Int Health. 2017 Apr;22(4):375-387
pubmed: 28102610
Stat Med. 2019 Oct 30;38(24):4888-4911
pubmed: 31436859
J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):e55-66
pubmed: 24977472
J Acquir Immune Defic Syndr. 2015 May 1;69(1):e24-30
pubmed: 25622060
J Int AIDS Soc. 2019 Apr;22(4):e25279
pubmed: 30993854
AIDS. 2010 Sep 10;24(14):2263-70
pubmed: 20683318
Trop Med Int Health. 2019 Jun;24(6):701-714
pubmed: 30938037
Trop Med Int Health. 2011 Oct;16(10):1297-313
pubmed: 21718394
Am J Epidemiol. 2020 Jan 31;189(1):77-78
pubmed: 31529036
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Int J Biostat. 2010 Feb 26;6(2):Article 7
pubmed: 20305706
Stat Med. 2018 Jul 20;37(16):2530-2546
pubmed: 29687470
MMWR Morb Mortal Wkly Rep. 2018 Jun 15;67(23):663-667
pubmed: 29902168
JAMA. 2018 Mar 20;319(11):1103-1112
pubmed: 29509839
J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):65-73
pubmed: 28542080
J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):45-51
pubmed: 24872139
PLoS Med. 2016 May 10;13(5):e1002015
pubmed: 27163694
PLoS Med. 2016 Aug 09;13(8):e1002107
pubmed: 27504637
Trop Med Int Health. 2015 Mar;20(3):365-79
pubmed: 25418366
PLoS Med. 2017 Jul 25;14(7):e1002357
pubmed: 28742880
Pac AIDS Alert Bull. 1999;(18):15-6
pubmed: 12349391
Am J Epidemiol. 2016 Apr 15;183(8):758-64
pubmed: 26994063
Am J Epidemiol. 2019 Aug 1;188(8):1569-1577
pubmed: 31063192
J Int AIDS Soc. 2019 Jul;22(7):e25331
pubmed: 31623428
Am J Public Health. 2018 May;108(5):616-619
pubmed: 29565659
AIDS. 2018 Jan 2;32(1):17-23
pubmed: 29112073
Lancet HIV. 2019 Oct;6(10):e715-e722
pubmed: 31515166
AIDS. 2007 May 11;21(8):965-71
pubmed: 17457090
J Int AIDS Soc. 2018 Jun;21(6):e25133
pubmed: 29939483
Afr J Reprod Health. 2018 Dec;22(4):72-80
pubmed: 30632724
J Int AIDS Soc. 2019 Oct;22(10):e25401
pubmed: 31647613
Clin Infect Dis. 2018 Nov 13;67(11):1643-1652
pubmed: 29889240
Afr J AIDS Res. 2012 Mar;11(1):65-73
pubmed: 25870899
J Int AIDS Soc. 2016 Jun 15;19(1):20919
pubmed: 27312984
Afr J AIDS Res. 2019 Mar;18(1):27-37
pubmed: 30782082
J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):e1-8
pubmed: 21084996
Soc Sci Med. 2017 Mar;176:52-59
pubmed: 28129547
PLoS Med. 2017 Jul 25;14(7):e1002358
pubmed: 28742819
PLoS Med. 2017 Nov 7;14(11):e1002407
pubmed: 29112692
PLoS One. 2019 Sep 6;14(9):e0222067
pubmed: 31490985
PLoS Med. 2017 Nov 7;14(11):e1002420
pubmed: 29112963